US › Healthcare

Immutep Ltd ADR (IMMP)

US · Healthcare · Biotechnology

$0.39+3.44%
Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue
$6.0M
Revenue YoY
+248.1%
Net profit
$-44.9M
Profit YoY
-108.8%
EPS
$0.00
EPS estimate
$0.00
Net margin
-744.4%

Key statistics

Market cap
$56.1M
Forward P/E
7.1
P/B
0.82
Book value
$0.47
EPS (TTM)
$-0.36
52-week high
$3.32
52-week low
$0.29
50-day MA
$0.41
200-day MA
$1.48
Beta
2.19

Analyst view

Analysts rate Immutep Ltd ADR a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $1.50.

Shareholding

Insiders
0.01%
Institutions
1.77%

Largest institutional holders

FundStake
BlackRock Inc0.55%
UBS Group AG0.51%
Meridian Wealth Management, LLC0.30%
Two Sigma Investments LLC0.08%
Citadel Advisors Llc0.05%
XTX Topco Ltd0.05%
TWO SIGMA SECURITIES, LLC0.04%
Virtu Financial LLC0.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immutep Ltd ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.